1554 Estimation of the global burden of mesothelioma deaths from incomplete national mortality data

Chimed‐Ochir, Odgerel; Takahashi, Ken; Sorahan, Tom; Driscoll, Tim; Fitzmaurice, Christina; Yoko-o, Makoto; Sawanyawisuth, Kittisak; Furuya, Sugio; Tanaka, Fumihiro; Horie, Seichi; Zandwijk, Nico van; Takala, Jukka

doi:10.1136/oemed-2018-icohabstracts.373

Cited by 2 publications

(3 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, many lower -income countries have not yet acquired the technology/infrastructure to diagnose and report mesothelioma and thus may be “missing” the disease burden. It is important for countries lacking mesothelioma data to utilize these estimates; that said, it is also important that they understand the method of imputation to derive the estimates (e.g., asbestos use is commonly imputed) as well as their limitations [ 10 ].…”

Section: Discussionmentioning

confidence: 99%

“…Based on data reported by 83 member states of the WHO, the worldwide age-adjusted mortality rate of mesothelioma increased 5.4% annually from 1994 to 2008 [ 9 ]. An updated analysis continued to show a general increase of the age-adjusted mortality rate, based on data judged to be “reliable” from 59 member states [ 10 ]. A GBD study estimated an 82% increase in global mesothelioma deaths from 1990 to 2016 [ 11 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Development of the “National Asbestos Profile” to Eliminate Asbestos-Related Diseases in 195 Countries

Arachi

Furuya²,

David

et al. 2021

IJERPH

Self Cite

View full text Add to dashboard Cite

Worldwide, 230,000+ people die annually from asbestos-related diseases (ARDs). The World Health Organization (WHO) recommends that countries develop a National Asbestos Profile (NAP) to eliminate ARDs. For 195 countries, we assessed the global status of NAPs (A: bona fide NAP, B: proxy NAP, C: relevant published information, D: no relevant information) by national income (HI: high, UMI: upper-middle, LMI: lower-middle, LI: low), asbestos bans (banned, no-ban) and public data availability. Fourteen (7% of 195) countries were category A (having a bona fide NAP), while 98, 51 and 32 countries were categories B, C and D, respectively. Of the 14 category-A countries, 8, 3 and 3 were LMI, UMI and HI, respectively. Development of a bona fide NAP showed no gradient by national income. The proportions of countries having a bona fide NAP were similar between asbestos-banned and no-ban countries. Public databases useful for developing NAPs contained data for most countries. Irrespective of the status of national income or asbestos ban, most countries have not developed a NAP despite having the potential. The global status of NAP is suboptimal. Country-level data on asbestos and ARDs in public databases can be better utilized to develop NAPs for globally eliminating ARDs.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Development of the “National Asbestos Profile” to Eliminate Asbestos-Related Diseases in 195 Countries

Arachi

Furuya²,

David

et al. 2021

IJERPH

Self Cite

View full text Add to dashboard Cite

show abstract

“…Although MPM is considered to be rare in comparison to other cancer types, the global incidence of MPM has increased significantly worldwide due to the past widespread and augmented use of asbestos in building materials over the past century. As such, The World Health Organisation estimates that approximately 125 million people are exposed annually worldwide to the carcinogenic mineral fibres in both the workplace and at home; accounting for an estimated 38,000 to 43,000 mesothelioma-related deaths each year [4][5][6]. There are few effective biomarkers and treatment options available to MPM patients in the clinical setting, attributing to a poor associated median survival of only 12-18 months following first-line standard chemotherapy with cisplatin and pemetrexed [7,8].…”

Section: Introductionmentioning

confidence: 99%

Pre-Clinical Research Advancements Relating to Improving the Diagnosis and Treatment of Malignant Pleural Mesothelioma: A Review

Johnson

Lee

Cheng

2021

Onco

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the lung lining that is predominantly associated with occupational exposure to asbestos. MPM is responsible for thousands of deaths worldwide every year, with the median survival of MPM of 8–14 months. There are limited biomarkers available in the clinic to effectively diagnose MPM, an invasive biopsy procedure is usually required to provide a definitive diagnosis. Due to the long latency period associated with MPM disease presentation, the cancer is usually at an advanced stage at the time of diagnosis where treatment options are largely ineffective at controlling disease progression. Previous MPM-based pre-clinical studies have made significant strides in determining the exact molecular mechanisms associated with asbestos carcinogenesis. Exploring less invasive blood-based biomarkers and treatment strategies involving targeted therapy, immunotherapy, and virotherapy is particularly important. Research in these areas is of crucial importance in relation to improving the rate of novel diagnostic biomarkers and treatment strategies progressing through to clinical trials and ultimately into the clinical setting. This review comprehensively summarises both previous and current pre-clinical research developments that have specifically contributed to an improved understanding of MPM disease biology, and the development of novel diagnostic biomarkers and treatment strategies.

show abstract

1554 Estimation of the global burden of mesothelioma deaths from incomplete national mortality data

Cited by 2 publications

References 7 publications

Development of the “National Asbestos Profile” to Eliminate Asbestos-Related Diseases in 195 Countries

Development of the “National Asbestos Profile” to Eliminate Asbestos-Related Diseases in 195 Countries

Pre-Clinical Research Advancements Relating to Improving the Diagnosis and Treatment of Malignant Pleural Mesothelioma: A Review

Contact Info

Product

Resources

About